Cell-Specific Retroviral Vector for In Vivo Immune Cell Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cell-based therapies, such as CAR T cell therapies, face challenges with complex supply chains, high costs, and logistical difficulties, and require significant processing time, while also being limited in their effectiveness against a variety of cancer types.
Innovation Solution
Development of a retroviral vector with a lipid bilayer envelope containing a single-domain antibody and Lassa virus envelope protein for cell-type specific targeting, combined with a cell-type specific promoter and nucleic acid molecule, allowing for efficient genetic modification of specific cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ex vivo methods with autologous cells are used, then patient safety is improved, but treatment complexity and cost increase
Solution Approach 1:
The therapy is segmented into two components: allogeneic T cells provide the cellular platform, while the retroviral vector delivers the CAR gene. This segmentation allows simplified manufacturing of T cells without requiring complex autologous cell processing chains, while maintaining safety through viral vector-controlled gene delivery
Solution Approach 2:
The retroviral vector acts as an intermediary that delivers the CAR gene into allogeneic T cells. This mediator enables the T cells to acquire target-specific functionality without requiring complex ex vivo manipulation, simplifying the supply chain while maintaining therapeutic efficacy
2Ease of manufacture
If allogeneic cells are used, then manufacturing complexity is reduced, but patient safety decreases
Solution Approach 1:
The invention changes the key parameter from cell source (autologous vs allogeneic) to gene delivery mechanism (retroviral vector). This parameter change allows using easily manufactured allogeneic T cells while controlling safety through the viral vector's regulated gene expression and controlled transduction
3Adaptability or versatility
If cell-based therapies are expanded to wider cancer types, then therapeutic versatility improves, but manufacturing complexity increases
Solution Approach 1:
The retroviral vector system provides a universal platform that can deliver CAR genes for targeting multiple different cancer types. The same basic T cell manufacturing process can be adapted to different cancer indications by changing only the CAR target antigen, not the underlying delivery mechanism, thus maintaining manufacturing simplicity across diverse applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The retroviral vector enables simplified logistics and reduced costs for cell-based therapies, effectively targeting and modifying a wide range of cell types, including T cells, myeloid cells, and other immune cells, with enhanced transduction efficiency and reduced immunogenicity.
Implementation Method 1
a single-domain antibody (sdAb) binding domain displayed on the exterior of the envelope that is cell-type specific
Implementation Method 2
a Lassa virus envelope protein displayed on the exterior of the envelope that is able to facilitate infection of the same cell type
Implementation Method 3
Lentiviruses are a family of retroviruses, which infect by inserting DNA into their host cells' genome
Implementation Method 4
infect by inserting DNA into their host cells' genome
Data Source
Figure 1
Figure 2A~2B
Figure 2C
AI summary
There is provided a viral vector having a lipid bilayer envelope comprising an antibody binding domain displayed on the exterior of the envelope that is cell-type specific; a viral envelope protein displayed on the exterior of the envelope that is able to facilitate infection of the same cell type; and a nucleic acid molecule comprising a promoter expressible in the same cell type. Further provided are methods of making the viral vector and methods of using the viral vector to modify cells and treat diseases / conditions.